Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | Gray zone lymphoma: pembrolizumab

Fernando Barroso Duarte • 20 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Hodgkin Lymphoma Lymphoma Antibodies Pembrolizumab

Dr Fernando Barroso Duarte, MD, Federal University of Ceara, Clinical Hospital, Fortaleza, Brazil, discusses the use of checkpoint inhibitors, including pembrolizumab in gray zone lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fernando Barroso Duarte

Allogeneic transplantation in elderly patients: insights from Brazilian registry data
2:23
Allogeneic transplantation in elderly patients: insights from Brazilian registry data
Fernando Barroso Duarte • 30 Mar 2025
Allogeneic transplantation for CMML from the Latin American perspective
2:20
Allogeneic transplantation for CMML from the Latin American perspective
Fernando Barroso Duarte • 30 Mar 2025
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era
3:31
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era
Fernando Barroso Duarte • 13 Feb 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Fernando Barroso Duarte • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Fernando Barroso Duarte • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Fernando Barroso Duarte • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Fernando Barroso Duarte • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals